Ampio Pharmaceuticals, Inc.AMPE announced that it has initiated the second phase III study on Ampion for the treatment of pain and inflammation due to osteoarthritis of the knee. The company reached a Special Protocol Assessment (SPA) agreement with the
Ampio (AMPE) Starts Final Phase III Study on Knee Pain Drug
